Wahyuni Hariyanto, Helmia Hasan

Abstract views = 645 times | downloads = 29194 times


Bronchiectasis is characterized by irreversible widening of the medium-sized airways (ectasia), with inflammation, chronic bacterial infection and destruction of the bronchial walls. This could be due to genetic constitusional state or episodic insidental state which not related to intrinsic imunity. The pathogenesis of bronchiectasis is a combination of repeated inflammation and parenchymal fibrotic, lead to bronchial wall weakening and bronchial irreversibly dilatation.“The vicious cycle” and P aeruginosa contributes on progression and severity of disease. The diagnosis of bronchiectasis is made on the basis of high-resolution computed tomography (HRCT) scan findings. Additional testmay be required in spesific clinical setting. Treatment strategies including antibiotic therapy in acute exacerbation and in controlling the microbial growth, therapy according to intrinsic conditional state, therapy to controll the excessive inflammation, promote bronchial hygiene, and consideration of surgery in some cases. In this review, we will describethe etiologies, pathogenesis, diagnostic investigation, and treatment strategies.


Bronchiectasis, Cole’s vicious circle, Mucocilliary clearence, P aeruginosa

Full Text:



Bilton D, Jones AL. European Respiratory Monograph: Bronchiectasis. European Respiratory Society. 2011;52:1–10

Neves PC, Guerra M, Ponce P, Miranda J, Vouga L.State-of-theart - Pulmonary Non-cystic fibrosis bronchiectasis. Interactive CardioVascular and Thoracic Surgery 2011;13: 619–625

Pamela J, McShane I, Edward T, Naureckas I, Gregory T, Mary E. Non–Cystic Fibrosis Bronchiectasis. American Journal Of Respiratory And Critical Care Medicine 2013; 188: 647–656

Iseman D, Chan ED.Bronchiectasisin: Murray and Nadels’s Textbook of Respiratory Medicine5th ed.2011;48: 853–876

Lambrecht BN, Neyt K, GeurzvanKessel CH. Pulmonary Defence Mechanisms and Inflammatory Pathways in Bronchiectasis. European Respiratory Monograph: Bronchiectasis2011;2:11–19

Barker AF. Bronchiectasis. New England Journal of Medicine 2002; 346: 1383–1393

Brown JS, Baxendale H, Floto RA. Immunodeficiencies Associated with Bronchiectasis. New England Journal of Medicine 2009; 211: 901–33

De Gracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996;153:650–655

Rademacher J, Welte T. Bronchiectasis-Diagnosis and Treatment. Deutsches Ärzteblatt International | Dtsch Arztebl Int 2011; 108(48): 809–15

Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patient with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 1997; 36:689–91

Elborn JS, Drain M. Assesment and Investigation of Adult with Bronchiectasis. Eur Respir Mon 2011; 2: 52–35

Perea PL, Screaton NJ. Radiological Feature of Bronchiectasis. European Respiratory Monograph: Bronchiectasis2011;2:44–65

Wat D, Foweraker JE. Microbiology of non-CF bronchiectasis. European Respiratory Monograph: Bronchiectasis2011;2:68–93

Haworth CS. Antibiotic treatment in adults with bronchiectasis. European Respiratory Monograph: Bronchiectasis2011;2:211–222

Pasteur M C, Bilton D, Hill A T. British Thoracic Society guideline for non-CFbronchiectasis. 2010

MauchleyDC, Mithell. Surgery for bronchiectasis.European Respiratory Monograph: Bronchiectasis2011;2:248–257


  • There are currently no refbacks.

View My Stats



Creative Commons License

JR (p-ISSN: 2407-0831e-ISSN: 2621-8372) is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.